Hanmi Pharmaceutical’s performance stood out in the outpatient prescription market with its solidified lead heralded by the introduction of its new combination drug. Daewon Pharmaceutical’s prescription volume has also soared vertically due to the boom in anti-inflammatory and cold medicines following a surge in the number of confirmed COVID-19 cases. Other major pharmaceutical companies also showed an increase in sales performance due to an increase in demand for COVID-19 symptom relief medications

According to the pharmaceutical research institution UBIST on the 18th, Hanmi took the sole lead among pharmaceutical companies in Korea and abroad in outpatient prescriptions with ₩194.3 billion in Q1